Arteris director trust sells shares, reports RSU grant
Arteris, Inc. director Saiyed Atiq Raza, through a revocable trust for which he serves as trustee, reported multiple stock transactions in the company’s common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Arteris, Inc. director Saiyed Atiq Raza, through a revocable trust for which he serves as trustee, reported multiple stock transactions in the company’s common shares. On June 3, 2026, the trust sold a total of 20,839 shares in open‑market trades at weighted average prices of $37.1294, $38.4583 and $37.6541 per share, under a pre‑arranged Rule 10b5‑1 trading plan.
The filing also shows bona fide gifts totaling 41,678 shares and a separate grant of 4,703 restricted stock units on June 2, 2026, which vest on the earlier of the first anniversary of the grant or the next annual stockholder meeting. Following these moves, the trust holds 160,839 shares and Raza’s direct holdings consist of 4,703 RSUs.
Insider Trade Summary 10b5-1
Net Seller: 20,839 shares
Net Sell
6 txns
Insider
RAZA SAIYED ATIQ
Role
Director
Sold
20,839 shs ($779K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | Common Stock | 20,839 | $0.00 | $0.00 |
| Gift | Common Stock | 20,839 | $0.00 | $0.00 |
| Sale | Common Stock | 8,332 | $37.6541 | $314K |
| Sale | Common Stock | 800 | $38.4583 | $31K |
| Sale | Common Stock | 11,707 | $37.1294 | $435K |
| Grant/Award | Common Stock | 4,703 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 4,703 shares (Direct);
Common Stock — 140,000 shares (Indirect, By Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012)
Footnotes (7)
- F1. Includes 4,703 restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the annual meeting of the Issuer's stockholders following the grant date, subject to the reporting person continuing to provide services to Issuer's Board through such vesting date. The RSUs have no expiration date. This grant of restricted stock was made on June 2, 2026, based on the average trading price of Arteris, Inc. common stock for the period from April 21, 2026 through June 2, 2026, which was $31.89.
- F2. The shares are transferred to Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the reporting person is the trustee.
- F3. The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the Reporting Person serves as trustee.
- F4. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on November 7, 2025.
- F5. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.27 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.63 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.32 to $37.31 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Open-market shares sold: 20,839 shares
Sale price 1: $37.1294/share
Sale price 2: $38.4583/share
+5 more
8 metrics
Open-market shares sold
20,839 shares
Total common stock sold on June 3, 2026
Sale price 1
$37.1294/share
Weighted average price for 11,707 shares sold
Sale price 2
$38.4583/share
Weighted average price for 800 shares sold
Sale price 3
$37.6541/share
Weighted average price for 8,332 shares sold
Gifted shares
41,678 shares
Two bona fide gift transactions of 20,839 shares each
RSU grant size
4,703 RSUs
Restricted stock units granted on June 2, 2026
Trust holdings after
160,839 shares
Common shares held by revocable trust post-transactions
Direct RSU holdings after
4,703 RSUs
Director’s direct restricted stock unit position post-transactions
Key Terms
restricted stock units ("RSUs"), Rule 10b5-1 trading plan, bona fide gift, weighted average sale price
4 terms
restricted stock units ("RSUs") financial
"Includes 4,703 restricted stock units ("RSUs"), each of which represents"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Rule 10b5-1 trading plan financial
"Transaction made pursuant to a 10b5-1 trading plan that was adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
bona fide gift financial
"transaction_code_description":"Bona fide gift""
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
weighted average sale price financial
"The price reported in Column 4 is a weighted average sale price."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Arteris (AIP) disclose in this Form 4?
Arteris disclosed that a trust associated with director Saiyed Atiq Raza sold 20,839 common shares in open‑market trades, made bona fide gifts totaling 41,678 shares, and reported a new grant of 4,703 restricted stock units to the director.
What restricted stock unit grant did Arteris (AIP) award to the director?
Arteris granted director Saiyed Atiq Raza 4,703 restricted stock units on June 2, 2026. Each RSU represents one share and will vest fully on the first anniversary of the grant date or immediately before the next annual stockholder meeting, provided he continues serving on the board.
Was the Arteris (AIP) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were made under a Rule 10b5‑1 trading plan adopted on November 7, 2025. Such pre‑arranged trading plans allow insiders to schedule stock sales in advance, reducing the significance of short‑term market timing in these particular trades.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates